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Abstract

Role of SARM1 Inactivation in Chronic Immune-Mediated Central Nervous
System Inflammation
By Kenneth Edward Viar, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2019
Director of Thesis: Unsong Oh, M.D., Department of Neurology
SARM1 is an injury-induced nicotinamide adenine dinucleotide nucleosidase
(NADase) that was previously shown to promote axonal degeneration in response to
traumatic, toxic, and excitotoxic stressors. This raises the question of whether a SARM1dependent program of axonal degeneration is central to a common pathway contributing to
disease burden in neurological disorders. The degree to and mechanism by which SARM1
inactivation decreases the pathophysiology of such disorders is of interest to establish the
rationale to pursue SARM1 as a therapeutic target. In this study, we compare the course
and pathology of experimental autoimmune encephalomyelitis (EAE) in Sarm1-knockout
(KO) mice and wild-type littermates to test the contribution of SARM1-dependent axonal
degeneration specifically in the context of chronic, immune-mediated central nervous
system (CNS) inflammation. The question of whether SARM1 loss in Sarm1-KO mice would
inhibit, promote, or have a negligible impact on EAE-induced axonal degeneration and
more broadly CNS inflammation was explored using a variety of analyses: quantification of
clinical score in a chronic EAE model, CNS immune infiltrate profile, axon initial segment
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morphology in layer V cortical neurons, axonal transport disruption and transection in the
lumbar spinal cord. Additionally, we have proposed a method for detecting SARM1
activation in situ using a novel SARM1-mCitrine bimolecular fluorescence complementation
(BiFC) technique. Successful implementation of such a molecular tool would allow for a
detailed, mechanistic approach to enhance our understanding of upstream intracellular
signals that trigger SARM1 activation.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease
affecting approximately 2.5 million people worldwide with over 400,000 to 900,000 in the
US alone (Walin et al., 2019). While the specific cause of MS is unknown, it is believed to be
influenced by both genetic and environmental factors that lead to aberrant immune
responses and subsequent neuro-axonal, astrocyte, and oligodendrocyte damage within the
CNS. MS imposes a significant burden on society due to the high costs of treatments and
limited employment opportunities patients experience with disease progression. Clinical
signs of MS usually begin between 20 to 40 years of age and incidence is nearly 3-fold more
common in females than males (Dendrou et al., 2015).
From onset, there are multiple disease courses and heterogeneous clinical
manifestations. The four major clinical courses are: relapsing-remitting MS (RRMS),
secondary progressive MS (SPMS), primary progressive MS (PPMS), and progressive
relapsing (PRMS). The first manifestation of disability prior to definitive diagnosis of MS is
referred to as clinically isolated syndrome (CIS). Approximately 85% of patients initially
experience RRMS characterized by intermittent recurrence of neurological deficits lasting
days or weeks with often complete or near complete recovery (Dargahi et al., 2017).
However, over time this course of relapsing clinical disease transitions to gradual
progression of symptoms, leading to accumulation of long-term disability in about 60% of
individuals that are initially diagnosed with RRMS. When these disabilities advance in the
absence of inflammatory relapses with no recovery, the patient has entered into the
secondary progressive phase of MS. PPMS accounts for a minority of patients and is
characterized by continuous disease progression for more than 1 year in the absence of

1

relapses. Finally, while rare, PRMS is characterized by continuous disease progression from
onset with added acute relapses and periods of continuous progression between relapses
(Filippi et al., 2018).
The pathological hallmark of MS is the formation of multiple demyelinating lesions
and astrocytic scaring in the CNS that are characterized by the breakdown of the bloodbrain barrier (BBB) resulting from pro-inflammatory cytokines. Inflammation is present at
all stages of MS, but is more pronounced in early relapsing stages that are characterized by
repetitive infiltration of peripheral immune cells. Immune infiltrates together with resident
activated microglia and astrocytes, are thought to contribute to oligodendrocyte injury,
demyelination and neuro-axonal injury through cell contact-dependent and independent
mechanisms. In contrast, progressive stages of tissue injury are largely due to oxidative
stress promoted by local immune cell activation (microglia and macrophage),
mitochondrial dysfunction, extracellular free iron accumulation, loss of myelin trophic
support, ionic imbalances, altered glutamate homeostasis, the failure of neuroprotective
and regenerative mechanisms, and a pro-inflammatory environment. This collectively leads
to chronic inflammation-induced CNS axonal degeneration with atrophy of the grey and
white matter (Filippi et al., 2018). New and existing demyelinating lesions are visualized
using magnetic resonance imaging (MRI), which has become a key diagnostic tool for
diagnosing MS and monitoring disease progression and response to disease-modifying
therapies (DMTs). A second diagnostic tool for a positive MS diagnosis is the presence of
oligoclonal bands in cerebrospinal fluid (CSF).
MS relapses were once thought to be primarily mediated by aberrantly-activated,
CNS-specific effector T cells that traffic into the CNS causing neuro-axonal injury,
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demyelination, and glial activation. We now understand the underlying immune
pathophysiology of MS to be much more complicated, as it involves many bidirectional
interactions and secretion of inflammatory mediators between immune cell types from the
periphery as well as resident glia of the CNS (Filippi et al., 2018). This inflammatory milieu
can disrupt the BBB and allow autoreactive immune cells in peripheral circulation access to
the CNS. While the majority of autoreactive T cells are eliminated during the process of
thymic maturation, a low frequency of nonregulatory T cells escape and are present even in
healthy individuals (Kaiko et al., 2008). These naïve, autoreactive T cells that recognize CNS
antigens have the potential to become activated and proliferate once it has encountered its
cognate antigen. CD4+ T helper 17 cells (TH17 cells) are critical regulators of MS disease
activity and are speculated to contribute to direct injury of oligodendrocytes and neurons
(van Langelaar et al., 2018). However, CD8+ T cells are found in higher frequency than CD4+
in the MS brain and their numbers correlate with axonal damage (Frischer et al., 2009). B
cells also have a significant role in the development of MS relapses. It is likely through
cellular immune interactions and a litany of inflammatory mediators (IL-6, GM-CSF, TNF
and lymphotoxin-α) that drive aberrant TH17/TH1 and myeloid cell responses (Bar-Or et
al., 2010). The prominent role of B cells in MS pathology is highlighted by the fact that Bcell-targeting therapies, such as antibodies directed against CD20 (pro-B phase Blymphocyte antigen 20), were effective at reducing MS disease activity (Palanichamy et al.,
2014). However, the administration of anti-CD20 antibodies does little to reduce the
presence of oligoclonal bands in CSF. Therefore, this therapy likely ameliorates symptoms
by downregulation of pro-inflammatory mediators (Filippi et al., 2018). This has offered
improved outcomes for patients suffering from PPMS that were otherwise resistant to
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immune ablation therapies. Anti-CD20 antibody therapy (ocrelizumab) and other disease
modifying therapies (DMTs) were initially tested using an animal models of MS known as
experimental autoimmune encephalomyelitis (EAE) (Palanichamy et al. 2014).
EAE has been optimized as the primary model for the study and development of
new therapeutic strategies in MS (Kaskow et al., 2018). EAE can be actively induced or
passively transferred. Active EAE relies on the priming of encephalitogenic T cells with
myelin antigens emulsified in complete Freund’s adjuvant (CFA) and in many cases
supplemented with an injection of pertussis toxin. This combination disrupts the BBB,
which normally impedes migration of autoreactive lymphocytes into brain parenchyma.
Some encephalitogenic antigens include: myelin oligodendrocyte glycoprotein (MOG),
proteolipid protein (PLP), myelin basic protein (MBP), myelin-associated glycoprotein
(MAG), and myelin-associated oligodendrocytic basic protein (MOBP). MOG has emerged as
an important target in MS because MOG-reactive T cells are detected at higher levels in MS
patients (Raddassi et al., 2011). MOG35-55 is the immunodominant peptide for MOG-induced
EAE in C57BL/6 mice (Encinas et al., 1999). Because many gene-specific knockout mice
have been generated on the C57BL/6 background, MOG-induced EAE has become a popular
disease model to study MS (Glatigny et al., 2018).
While not a perfect model of MS, EAE does share many pathological characteristics
with MS. The primary inflammatory feature of EAE, caused through dysfunction of the BBB
and aberrant activation of the immune system provokes a similar assortment of
neurodegenerative symptoms. Axonal injury is among the most notable, and has been
associated with inflammation in all MS stages (Frischer et al., 2009). The formation of
axonal spheroids and transected axons has been shown to occur early in disease and is a

4

major determinant of disability accumulation (Trapp et al., 1998; Vogt et al., 2009).
Disruption of functional domains of myelinated axons can also observed in both EAE and
MS (Clark et al., 2016; Griggs et al., 2017). The CNS does possess the capacity for repair and
remyelination, which in early relapsing-remitting stages can contribute to full clinical
remission. However, once an axon is completely severed, repair mechanisms are
insufficient (Ellwardt et al., 2014).
Current therapies largely focus on immunomodulatory or immunosuppressive
actions that have been shown to improve outcomes in early relapsing remitting forms of
MS (Ellwardt et al., 2014). However, immune ablation in progressive courses of MS is less
effective, necessitating novel approaches to improve and diversify treatment options. With
axonal degeneration identified as a major determinant of disability accumulation, targeting
the underlying cellular mechanisms that initiate this process has the potential to mitigate
disease burden, slow progression, and thus improve outcomes for those with progressive
MS. (Barkhof et al., 1999; Trapp et al., 1998)
This begins with understanding how the mechanisms behind current models of
Wallerian degeneration relate to CNS inflammatory disorders. SARM1 (sterile alpha and
TIR motif-containing 1) and nicotinamide mononucleotide adenylyltransferase (NMNAT)
are proteins involved in NAD (Nicotinamide adenine dinucleotide) metabolism and
established opposing elements in programmed axonal degeneration (Mack et al., 2001;
Osterloh et al., 2012). Because NAD is a cofactor found in all cells and is essential to redox
metabolism during beta oxidation, glycolysis and oxidative phosphorylation, its
concentration within the cell must be closely regulated and kept within a narrow
physiological range. NMNAT catalyzes the last step in converting nicotinamide
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mononucleotide (NMN) to NAD, both in the de novo synthesis and salvage pathways. A
transgenic form of NMNAT, originally characterized in the “Wallerian degeneration slow”
(Wlds) mouse, was shown to confer enhanced axonal survival following axonal injury, but
the exact mechanism behind this effect is not yet fully understood (Brazill et al., 2017). The
role of NMNAT in regards to enhanced NAD biosynthetic capacity is well established, which
was initially thought to simply override the NAD-cleaving activity of SARM1 thus
preventing the local metabolic stress leading to programmed axonal degeneration
(Girouard et al., 2018). However, recent work involving NMNAT overexpression in neurons
has shown that NMNAT-mediated axon protection may also hinge on its ability to block
SARM1 signaling through an enzyme-independent, chaperone function as it has been
shown to confer neuroprotection without altering NAD synthesis (Brazill et al., 2017).
While the exact nature and individual contribution of each of these inhibitory mechanisms
is yet to be determined, it is clear that NMNAT acts upstream of SARM1 to promote
neuronal maintenance and that SARM1 activation triggers axon degeneration locally via
NAD destruction.
Increased NAD levels through altered NMNAT activity, as in the Wlds mouse, and
Sarm1 deletion are among the most characterized methods to delay Wallerian
degeneration. Because SARM1 deletion, and not Wlds expression, resulted in longer-lived
neuroprotection in mouse models of severe axonopathy, SARM1 depletion appears to have
analytical and therapeutic advantages over Wlds (Gilley et al., 2017). This warrants a closer
look at the four functional domains of SARM1 (Figure 6B): a mitochondrial localization
signal (MLS), an autoinhibitory N-terminus region consisting of armadillo/HEAT motifs
(ARM), two sterile alpha motifs (SAM) responsible for multimerization, and a C-terminus
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Toll/Interleuken-1 receptor (TIR) domain. Under healthy conditions, SARM1 exists as an
inactive dimer with the two ARM domains preventing the association of adjacent TIR
domains that is required for NADase activity (Figure 6D) (Gerdts et al., 2013; Summers et
al., 2016). Following axonal injury, inhibition is removed and TIR-mediated NADase activity
is restored (Figure 6E). SARM1 NADase activity was found to be essential in the initiation
of axonal degeneration following axotomy and later in traumatic, toxic, and excitotoxic
injury. This raises the possibility that a SARM1-dependent program of axonal degeneration
could be central to a common pathway. Therefore, demonstrating the role of SARM1 in
axonal pathology associated with CNS inflammation, in which a similar milieu of
inflammatory stressors is observed, would identify SARM1 as an obstacle to axonal
protection in MS and other neuroinflammatory disorders.
Central to that goal would be a method to observe the neuroinflammatory
conditions of the EAE model in the absence of functional SARM1 protein. A SARM1 globalknockout mouse (B6.129X1-Sarm1tm1Aidi/J) was developed with congenic, targeted
mutations in exons 3-6, rendering it inactive (Kim et al., 2007). With this mouse model, we
pursued our first aim to define the effect that SARM1 inactivation had on axonal pathology
in the context of chronic, immune-mediated CNS inflammation. First, we sought to establish
a difference in how Sarm1-KO and wild-type mice responded to neuroinflammatory insults
by scoring the motor deficits that resulted from EAE disease activity. Then, shift to
characterizing the mechanism by which loss of SARM1 mediated any such difference.
Analyzing CNS immune infiltrate profiles of Sarm1-KO and wild-type mice during EAE was
an important first step. Because SARM1 is expressed in neurons as well as immune cells, it
remained to be clarified whether any clinical effect would be attributable to loss of
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neuronal SARM1, immune cell SARM1 or both. Next, we measured the differences in axon
initial segment (AIS) number and length in layer V cortical neurons in Sarm1-KO compared
to wild-type littermates. Then, quantified axonal pathology within the lumbar spinal cord
during EAE by looking at axonal transport disruptions as well as transection. We
hypothesized that there would be a reduction in axonal pathology observed in Sarm1(-/-)
mice induced with experimental autoimmune encephalomyelitis (EAE) when compared to
wild-type Sarm1(+/+) littermates, thereby confirming the contribution of SARM1 to axonal
degeneration in CNS inflammatory disorders.
Our second aim was to demonstrate a molecular technique able to screen for
SARM1-activation in situ using bimolecular fluorescence complementation. Successful
implementation of such a molecular tool would allow for a detailed, mechanistic approach
to enhance our understanding of upstream intracellular signals that trigger SARM1
activation. Because SARM1 dimerization and association of two TIR domains is an essential
step in activation, two SARM1 proteins each with a different complementary fragment of
mCitrine fused to the TIR domain can be used to signify when this activation occurs. This is
based on complementation between N-terminal and C-terminal fragments (–N172 and –
C67) of monomeric Citrine, a variant of green fluorescent protein (GFP). These fragments
are individually non-fluorescent, but when brought in close proximity to one another
fluorescence is restored (Hu et al., 2005). This is accomplished in situ when two SARM1BiFC plasmids coding for the complementary fragments of Citrine fused to the TIR domains
are transfected into neurons, but only when brought in close proximity to one another as in
the case during SARM1 activation. Thus, our second aim goals were to design, transfect,
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and confirm expression of SARM1-mCitrine fusion proteins using HEK293 cells and
western blot.
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Methods
Animals
Sarm1 KO mice (B6.129X1-Sarm1tm1Aidi/J) were obtained from Jackson Laboratories and
maintained on a C57BL/6J (Kim et al., 2007). A colony of Sarm1 KO mice were maintained
locally by heterozygous mating to produce homozygous Sarm1 knockout
[Sarm1(-/-)], heterozygotes [Sarm1(+/-)], and wild-type littermates [Sarm1(+/+)]. In addition,
Thy1-YFP-H mice [B6Cg-TgN (Thy1-YFP-H)2Jrs, Jackson Laboratories stock number
003782] from an established colony maintained locally, were crossed with Sarm1-KO mice
to produce Sarm1(-/-)/Thy-1-YFP(+) and Sarm1(+/+)/ Thy-1-YFP(+) in select experiments.
Both adult males and females were included, all between 6 – 12 weeks of age unless
otherwise stated. Animals were housed in an Assessment and Accreditation of Laboratory
Animal Care (AAALAC) accredited vivarium of Virginia Commonwealth University on an
alternating 12-hour light and dark cycle with food and water provided ad libitum. All
studies involving mice were conducted in accordance with the methods outlined in
protocols approved by the Institutional Animal Care and Use Committee of Virginia
Commonwealth University.

Experimental autoimmune encephalomyelitis
An emulsion containing myelin oligodendrocyte glycoprotein (MOG33-55, AnaSpec) peptide
and Complete Freund’s adjuvant (CFA; Chondrex) supplemented with 2mg/ml of
Mycobacterium Tuberculosis (Invitrogen Life Technologies) was prepared using glass
syringes and emulsifying needle until viscous and white in color. Mice were injected
subcutaneously at two sites over the shoulder with 100 µl of emulsion (50 µl per site)
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containing 200 µg MOG33-55. This was supplemented with an intraperitoneal (i.p.) injection
of 300 ng pertussis toxin (PT; List Biological Labs) in 200 µl PBS delivered at time of
immunization with an additional PT injection 48 hours later. Clinical symptoms of disease
and animal weight were recorded from day 5 post-immunization to day 42 (Clark et al.,
2016). Absorbent bedding and moist food were introduced when the mice reached a
clinical score of 3 or more and given daily subcutaneous saline injections when above 3.5.
The clinical scores were applied as previously described (Louveau et al., 2018), based on
the following criteria:
A score of 0 indicated the mouse was clinically normal.
A score of 1 was characterized by complete loss of muscle tone in tail. A score of 0.5 was
given for incomplete loss of muscle tone in tail.
A score of 2 was characterized by mild hind limb paresis. The animal demonstrated
decreased dexterity/coordination with hind limbs and was unable to right itself
immediately if turned on back. Animal gait was mostly normal, but uncoordinated at times.
A mouse cage wire was used to determine the degree of hind limb impairment by placing
mouse on flat portion parallel with the wire bars and then hind limbs repetitively
suspended and dropped onto wire allowing approximately 3 seconds between 5 separate
tests. If one or both of the hind legs slipped through cage wire in 3 out of 5 tests, then a
score of 2 was given. A score of 1.5 was given for a mouse that demonstrated some degree
of hind limb impairment, but fell below the 3-out-of-5 threshold. The observed position of
the hindlimbs while suspended aided in this distinction. A mouse that has a score greater
than 1 does not demonstrate the natural widened-hindlimb stance that a clinically normal
11

mouse would while suspended, but instead holds legs and feet more centered below hips. If
an animal displayed this altered, narrow hindlimb stance while suspended and was unable
to prevent its legs from falling though the cage in at least 1 or 2 of the 5 tests, then a score
of 1.5 was given.
A score of 3 was mainly characterized by severe hind limb impairment or paralysis. This
was evident in abnormal gait and commonly unkept coat due to difficulties with grooming.
A mouse cage wire was used to determine the degree of hind limb impairment by placing
the mouse on the flat portion of the cage wire with bars running parallel with the mouse’s
body and inverting it. The cage wire was maintained in inverted position for 3 seconds. To
ensure the animal’s safety, this test was conducted over top of the cage with a free hand
below to catch the mouse in the event that it could not support itself. This test was
repeated twice. If the mouse was unable to support itself for a period of 3 seconds both
times, a score of 3 was given. If the animal fell during one test and supported itself for a
minimum of 3 seconds during the other, or if the animal was able to support itself for a
period of 3 seconds hanging solely by fore limbs, a score of 2.5 was given. If it was apparent
that the animal was unable to adequately grip the bars when slightly tilted, the inversion
test was not necessary and additional testing was used.
A score of 4 is characterized by complete hind limb paralysis and forelimb paresis. The
animal’s hindlimbs were observed to be completely immobilized, but was still able to move
with use of forelimbs, and commonly displays unkept coat due to difficulties with
grooming. If the animal was capable of minor hindlimb movement (“paddling”) while still
able to effectively move with the use of its forelimbs, then a score of 3.5 is given.
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A score of 5 was characterized by paralysis of all limbs and moribund state. The animal was
immobile and presented with irregular breathing. If an animal displayed a score of 5, it was
euthanized. A score of 4.5 was given if the animal’s muscles in legs and lower back showed
signs of atrophy, but was still capable of limited locomotion and breathing normally.
Tissue fixation and cryoprotection
Mice were given a lethal dose of anesthetics by intraperitoneal (i.p.) injection of a 2.5%
solution of avertin (2,2,2 tribromoethanol, Sigma-Aldrich) (0.016 mL/g body weight). Mice
were then transcardially perfused first with room-temperature normal saline followed
immediately by 4% paraformaldehyde. The entire CNS was collected, cryoprotected with
30% sucrose, and frozen in Tissue-Plus®O.C.T. compound (Thermo Fisher Scientific). Fixed,
frozen brains and spinal cords were then serially sliced into 30-μm or 20-μm-thick sections
with a cryostat (Leica), collected onto Superfrost™ Plus slides (Thermo Fisher Scientific),
and stored in manual-defrost freezer at -20°C (Benusa et al., 2017; da Mesquita et al.,
2018).

Antibodies
Axon initial segments (AISs) were visualized using mouse monoclonal antibodies directed
against ankyrin-G (AnkG; Millipore; N106/36, 1:500) Neurons were identified using the
NeuN antibody (Millipore; 1:500). To assess axon spheroid formation, antibodies directed
against amyloid precursor protein (APP; ThermoFisher; #36-6900; 1:400) was used. All
secondary antibodies were obtained from Invitrogen Life Technologies (AlexaTM Fluor) and
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used at a dilution of 1:500. In all instances, DAPI (4′,6-diamidino-2-phenylindole;
Invitrogen) was used as a nuclear stain.

For immunoblot analysis of recombinant SARM1-mCitrine fusion proteins, either a mouse
monoclonal antibody directed against human SARM1 (Biolegend; #696602; 1:250) or
rabbit monoclonal antibody directed against green fluorescent protein (Novus NB600308SS; 1:1000) were used. This was followed by the appropriate HRP-conjugated
secondary (1:10,000) and immunoreactive bands were visualized using the SuperSignal
West Femto kit (Thermo Scientific).

Immunohistochemistry
Brains and spinal cords were immunolabeled as previously described (Sato-Bigbee et al.,
1999; Dupree et al., 1999). A hydrophobic barrier was formed on the slide around the
tissue using a PAP pen (abcam), and then washed several times to remove OCT. Nonspecific
antibody binding was blocked by incubation of the tissue on slides for 30 min in a PBS
blocking solution containing 4% cold water fish skin gelatin (Electron Microscopy Sciences,
#25560) and 0.5% Triton-X, which was used in all subsequent antibody steps. The tissue
was then incubated overnight at 4oC with appropriate primary antibodies. After several
washes in PBS, the tissue was incubated with appropriate secondary antibodies for 90
minutes. After several washes, slides were mounted with Vectashield™ (Vector
Laboratories, Burlingame, CA); and imaged using fluorescence microscopy. An additional
antigen-retrieval step was performed for APP as well as Ankyrin-G staining prior to the
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above blocking step. Tissue was incubated in a citric acid buffer (100mM citric acid pH 6.0)
for 30min at 45oC, and then followed by three consecutive rinses in PBS.

Microscopy/Quantification
AIS analysis
Animals were actively induced with EAE and sacrificed 42 days post-induction. All images
were collected using a Zeiss LSM 710 confocal laser scanning microscope (Carl Zeiss
Microscopy) housed in the VCU Department of Anatomy and Neurobiology Microscopy
Facility. Three confocal z-stacks, each spanning an optical distance of 15 μm, using a pin
hole of 1 Airy disc unit and Nyquist sampling were collected from neocortical layer V (-1.22
to -1.94 from bregma) for 2 sections per mouse resulting in 6 images per animal for AIS
quantitation. Images were taken with a 40X oil-immersion objective with a numerical
aperture of 1.3; optical slice thickness was 0.44 µm, using a scan average of 2.
X, Y, and Z image dimensions were 212.5 µm × 212.5 µm × 15.00 µm, respectively. The gain
and offset values were kept constant for all images. AISs were manually traced using
ImageJ software to obtain length measurements and counts. All those below 10 µm in
length or sharing the border of the X and Y planes were excluded (Benusa et al., 2017).

Axonal Degeneration Quantification
Animals were actively induced with EAE and sacrificed 42 days post-induction. Sequential
coronal sections of lumbar spinal cords from Sarm1(-/-) and Sarm1(+/+) animals were
analyzed using fluorescent microscopy. Disruption in axonal transport of proteins such as
APP can be used as a marker of axonal injury. Accumulation of APP in axonal spheroids is a
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reliable marker for acute axonal damage. Therefore, we used APP immunostaining to
quantify axonal injury in lumbar spinal cords. All images were collected using a Zeiss
AxioImager Z2 (Carl Zeiss Microscopy) equipped with a Q-Imaging Retiga-2000R color CCD
camera. Six representative, nonoverlapping images from a coronal lumbar spinal cord
section were taken at 240 µm intervals throughout the spinal cord with a 20x/.8NA
objective; image dimensions were 580 µm x 434 µm. This resulted in 24 images
predominantly of the lateral-most spinocerebellar tracts, but also included those of the
dorsal column and spino-olivary fibers. The gain and offset values were kept constant for
all images. Total APP area (µm2) was calculated using ImageJ batch analysis software after
manual brightness and contrast adjustments (Benusa et al., 2017). Image files were coded
to blind research personnel to genotype during image analysis.

Axonal Transection Quantification.
Animals were actively induced with EAE and sacrificed 14 days post-induction. Sequential
coronal sections of lumbar spinal cords from Sarm1(-/-)/Thy-1-YFP(+) and Sarm1(+/+)/ Thy1-YFP (+) animals expressing YFP within axons were analyzed using fluorescent microscopy.
All images were collected using a Zeiss AxioImager Z2 as described above. Six
representative, nonoverlapping images from a YFP-labeled lumbar spinal cord section
were taken at 240 µm intervals throughout the spinal cord with a 20x/.8NA objective;
image dimensions were 580 µm x 434 µm. This resulted in 24 images predominantly of the
lateral-most spinocerebellar tracts, but also included those of the dorsal column and spinoolivary fibers. The number of transected axons were counted using ImageJ software. Three
equally-spaced, perpendicular lines were superimposed on the images and the number of
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intact and severed axons were determined based on the number of YFP-labeled axons that
crossed each line. Axons spanning multiple vertical lines were only counted once.

Embryonic Neuronal Culture
Prior to dissection, cell culture surfaces were coated with poly-D-lysine (0.1 mg/mL; SigmaAldrich) and appropriate amounts of Neurobasal® (NB; Thermo Fisher Scientific) media,
NB media + glutamate, and NB media + glutamate + trypsin/DNAse were prepared as
previously described in (Clark et al., 2017). Timed-pregnant Sarm1(-/-) and Sarm1(+/+)
females were euthanized when pups were at an embryonic age of 15.5 days using
isoflurane overdose. All subsequent dissections were performed using sterile technique in
a laminar flow hood. The uterus and embryos were removed and washed in two
consecutive steps with sterile PBS. The embryos were dissected from the amniotic sacs and
decapitated prior to being temporarily stored in a dish containing NB media. Three brains
of both Sarm1(-/-) and Sarm1(+/+) pups of were then removed using a dissecting microscope,
then placed individually in NB media. The brains were split into two hemispheres,
meninges and hippocampus removed, and the cerebral cortex was dissected and placed
into an eppendorf tube containing 1 ml of NB media. The cortex fragments were then
washed twice, resuspended in NB media + glutamate + trypsin/DNAse, placed in a 37oC
incubator on a preheated rotator, and continually rotated for 30 minutes. Cortex fragments
were then centrifuged at 300 x g for 2 minutes, washed twice with NB medium, and
resuspended in 1ml of NB media + glutamate. A single-cell suspension was achieved
through careful trituration followed by filtration through a 70 µm filter (J Beaudoin et al.,
2012). Cortical neurons were then counted by hemocytometer and cultured on poly-D-
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lysine-coated plates. Cortical neuron cultures were maintained in a cell culture incubator at
37oC, with NB media changes every 72 hours (DIV) (Clark et al., 2017).

Fluorescence-activated cell sorting (FACS) analysis
Following euthanasia, animals underwent transcardiac perfusion with up to 50 ml of
normal saline using a rate-controlled pump. Thoracolumbar cords (from T2 to caudal end)
were expelled out of the spinal column using hydraulic pressure manually applied through
a 19-gauge needle and syringe filled with phosphate buffered saline (PBS). Cords were
minced using a McIlwaine tissue chopper (Mickle Laboratory Eng. Co., UK), then
enzymatically dissociated in RPMI containing 2.5 mg/ml collagenase D (Roche Diagnostics,
Indianapolis, IN) and DNaseI (20 µg/ml, Sigma Aldrich) for 45 minutes at 37oC on a rotator.
Cells were passed through a 70 µm filter, washed in RPMI, resuspended in 30% isotonic
Percoll (GE Healthcare) in PBS, then centrifuged at 500 x g for 10 min. Supernatant was
removed. Cell pellets were washed and resuspended in RPMI. Cells were aliquoted into
tubes and washed in FACS buffer (0.1% sodium azide and 2% fetal calf serum in PBS). Cells
were incubated with Fc block (anti-mouse CD16/CD32 antibody, BD Biosciences) for 5
minutes prior to addition of fluorochrome-conjugated antibodies against CD3 (clone 17A2),
CD4 (clone GK1.5), CD45 (clone 30-F11), CD19 (clone 1D3), CD8 (clone 53-6.7), CD11b
(clone M1/70), CD11c (clone N418), Ly6C (clone HK1.4), Ly6G (clone 1A8-Ly6G) and
NK1.1 (clone PK136). Following 30-minute incubation in the dark at 4oC, cells were washed
in FACS buffer. Count beads (CountBright, Thermo Fisher) were added to each sample to
allow absolute count determination. FACS data was acquired on a flow cytometer (FACS
Canto, BD Biosciences). Data were analyzed using FlowJo software (FlowJo, LLC).
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HEK293 Cell Culture/Transfection
HEK 293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) at 37°C in a 5%
CO2 humidified atmosphere. Transfection was performed with the Lipofectamine™ 3000
reagent transfection kit (Invitrogen) according to the manufacturer's instructions. HEK293
cells were 70% confluent at time of transfection. Immediately prior to transfection, 1.5 µl of
lipofectamine 3000 reagent was added to 23.5 µl of opti-MEM™ (Thermofisher) and gently
vortexed for 2-3 seconds. In a separate microcentrifuge tube, 1µl of P3000 reagent was
added to 24 µl of opti-MEM containing DNA 500 ng of Sarm1 expression vectors for
bimolecular fluorescence as detailed in Table 1. The diluted DNA + P3000 reagent was
added to the lipofectamine reagent in a 1:1 ratio, and the solution was allowed to incubate
for 15 minutes at room temperature before being added to HEK293 cells in a 24-well plate.
Cells were harvested 72 hours later, and cell lysate analyzed using western blot for
presence of transgenic SARM1 proteins (Moreno et al. 2016).

Western Blot
Immunoblot analysis was performed according to the method described previously in
(Hazelton et al. 2009). Following transfection, HEK293 cells were lysed in RIPA lysis buffer
(0.5 % NONIDET P-40, 1 % Triton X-100, 150 mM NaCl, 10 mM Tris pH 7.4) supplemented
with protease inhibitor cocktail (Sigma; P8849). The BioRad DC protein assay was used to
determine total protein concentration, and 20 µl of total cell lysate per sample was
resolved on 4-20% Mini-Protein® TGX™ gels and transferred to polyvinylidene fluoride
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(PVDF) membranes (Invitrogen) using the Trans-Blot® Turbo™ System (Bio-Rad). The
membranes were washed and incubated in 5% non-fat milk in phosphate-buffered saline
with 0.05% Tween 20 (PBST) for 30 minutes, then incubated overnight at 4 °C with antihuman SARM1 (Biolegend; #696602; 1:250) or anti–GFP (Novus NB600-308SS; 1:1000)
under continuous agitation. This was followed by washing the membranes in PBST and
incubation for 45 minutes with appropriate HRP-conjugated secondary (1:10,000) (Cell
Signaling Technology) antibody. Immunoreactive bands were visualized using the
SuperSignal West Femto kit (Thermo Scientific) (Peach et al. 2012).

Statistical Analysis
Mann–Whitney was used for two group comparisons. Where appropriate, KolmogorovSmirnov test was used as a test of normality. T-test was used for two group comparisons
for normally distributed data. Statistical analysis was performed using Prism software
(GraphPad).

20

Results and Discussion
The contribution of SARM1-dependent program of axonal degeneration to the
pathophysiology of immune-mediated CNS inflammatory disorders was previously
unknown. Prior studies showed that the loss of SARM1 was beneficial in a number of
animal models of neurological disorders. Sarm1 KO mice showed reduced clinical severity
and reduced axonal loss in an animal model of traumatic brain injury (Henninger et al.
2016), and had less axonal degeneration in animal models of peripheral neuropathy due to
chemotoxicity or metabolic derangement (Geisler et al., 2016; Turkiew et al., 2017).
However, loss of SARM1 had no significant impact on axonal loss or clinical course of
mutant SOD1 model of amyotrophic lateral sclerosis (Peters et al., 2018). Therefore, the
contribution of SARM1 is likely to be disease-specific, with severity and duration of insult
potentially dictating the therapeutic potential of SARM1 inactivation. In this thesis, the
course and pathology of EAE in Sarm1-KO mice and wild-type littermates were compared
to test the effect of SARM1 inactivation on axonal degeneration in the setting of chronic
immune-mediated CNS inflammation.
Sarm1-KO and wild-type littermates were actively induced to undergo EAE. There
was no difference in the incidence of EAE between Sarm1-KO and wild-type littermates
(94% vs. 100%, p > 0.99, Fisher’ exact test). The clinical score comparison of Sarm1-KO and
wild-type littermates (Figure 1) reflects a modest reduction in motor deficits experienced
during a 42-day chronic EAE time course. While peak of clinical severity and onset of
symptoms were similar, there was a divergence in mean clinical score between genotypes
beginning at about 3 weeks post-induction. From that point, Sarm1-KO mice exhibited a
faster recovery from motor deficits than wild-type littermates with differences in score
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becoming statistically significant by week 6. Because SARM1 is expressed in neurons as
well as immune cells, it remained to be clarified whether this clinical effect was attributable
to loss of neuronal SARM1, immune cell SARM1 or both. Therefore, additional analysis was
needed to clarify the mechanism by which SARM1 inactivation mediates reduction in longterm clinical severity in EAE.
SARM1 expression in immune cells could potentially affect the course of CNS
inflammatory disorders based on its N-terminal TIR domain that could influence immune
response by modulating signaling downstream of the Toll-like receptor (TLR) (Fekonja et
al., 2012). To address this question of whether SARM1 TIR domain loss had an impact on
immune cell activation and subsequent infiltration into the CNS during EAE, we performed
FACS analysis of CNS infiltrating immune cells during the peak of clinical severity (14 days
post-induction) for Sarm1-KO and wild-type littermates (Figure 2). There were no
significant differences in the number of CNS inflammatory cells between Sarm1-KO and
wild-type littermates, including T cells, B cells, macrophage, natural killer (NK) cells and
neutrophils, suggesting that SARM1 inactivation did not alter inflammatory cell
recruitment into the CNS. In addition, ex vivo antigen (MOG35-55) recall response data from
our laboratory showed no difference between Sarm1-KO and wild-type littermates with
respect to peripheral immune activation of EAE (data not shown). These results are
consistent with the clinical observation that onset and incidence of EAE are comparable
between the genotypes. It remains possible that CNS immune cell infiltration might differ
between Sarm1-KO and wild-type littermates at later time points and it may be informative
to choose a later time point to determine if immune infiltrates correspond to the
divergence in clinical score at week 3 post-induction and beyond.
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Without a discernable difference in immune infiltrates at peak EAE disease activity,
we explored the effect of SARM1 inactivation on axonal degeneration through analyses of
AIS morphology in layer V cortical neurons, axonal transport disruption, and transection in
the lumbar spinal cord. These analyses were designed to measure neuroprotective effects
of SARM1 loss, relative to a SARM1-dependent program of axonal degeneration, broadly
across the CNS at various disease time points.
AIS of layer V primary somatosensory cortex was previously shown to be vulnerable
in EAE (Clark et al., 2016). To determine whether AIS loss in EAE could be ameliorated by
Sarm1-KO, we quantified AIS in the layer V primary somatosensory cortex by
immunohistochemistry. We found no significant difference between Sarm1-KO and WT
littermates with respect to AIS length or total AIS count within layer V of the primary
somatosensory cortex (-1.2 to -1.9 Bregma) at 42 days post-induction (Figure 3). It has
been reported that disruption in AIS organization in EAE is not the consequence of
demyelination, neuronal death or axonal transection, but is associated with reactive
microgliosis (Clark et al., 2016). Prior research also indicated that AIS loss in EAE
corresponded to severity of clinical scores (Clark et al., 2016). One possible interpretation
of our result is that SARM1 does not contribute to AIS loss in EAE. We have not, however,
ruled out the possibility that EAE did not result in substantial AIS loss in our experiments.
It remains possible that there may have been insufficient disease activity in our
experimental animals to result in substantial AIS loss. A greater number of animals with
clinical scores of 3 and above that extend into the 3rd week post-induction may be
necessary to see a greater effect. Future experiments will include additional control
animals (mice immunized with only CFA at induction) to confirm AIS loss in our
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experimental animals. Future analyses will also include measures of microglial activation in
layer V cortex to provide information on the presence or absence of cortical inflammation
in our experimental animals.

25

Figure 2. CNS inflammatory infiltrates in Sarm1-KO and wild-type littermates at peak
of EAE clinical severity. Thoracolumbar cords from Sarm1-KO and wild-type littermates
at day 14 post induction were enzymatically dissociated into single-cell suspension then
analyzed by FACS. Cells were identified by immunophenotypic markers as microglia
(CD45lo, CD11c+, CD11b+), macrophage (CD45+, CD11b+, CD11c+, Ly6c+), total T cells (CD3+),
T helper cells (CD3+,CD4+), cytotoxic T cells (CD3+,CD8+), B cells (CD19+), natural killer cells
(NK1.1+), neutrophils (Ly6GHi, CD11b+). Shown are absolute counts for Sarm1-KO (circle)
and wild-type (square) for the indicated immune cell types.
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Figure 3. Axon initial segment (AIS) number and length in layer V cortical neurons of
Sarm1-KO and wild-type littermates during chronic EAE (42 days post-induction).
A) Representative maximum intensity projection of Sarm1(-/-) mouse (S1BF -1.68 Bregma).
B) Representative maximum intensity projection of wild-type Sarm1(+/+) mouse (S1BF -1.94
Bregma). C) Quantification of mean AIS length. D) Quantification of total AIS count (n=9; 6
images per animal).
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As previously mentioned, inflammatory lesions in EAE models are predominantly
located within the spinal cord, whereas in MS CNS inflammation involves both brain and
spinal cord. However, EAE pathology in the lumbar spinal cord can still serve as a sufficient
model for inflammation-induced axonal injury similar to what is seen in white matter
lesions of MS. This is especially relevant as past studies identified axonal damage in the
form of altered axonal trafficking and axonal transection within inflammatory MS lesions as
a major determinant of disability accumulation (Trapp et al., 1999; Singh et al., 2017).
Disruption in axonal transport of proteins such as APP can be used as a marker of
axonal injury. Accumulation of APP in axonal spheroids is a reliable marker for acute
axonal damage (Schultz et al., 2017). Therefore, we used immunostaining to quantify
axonal injury in lumbar spinal cords of Sarm1-KO and wild-type littermates (42 days postinduction). There was a decrease in mean APP area (µm2) observed in Sarm1-KO mice
compared to wild-type littermates that did not reach statistical significance (Figure 4,
p = .31, Mann-Whitney). One possible interpretation is that SARM1 loss resulted in a
modest reduction in inflammation-induced axonal damage that requires a larger sample
size to detect a statistically significant difference. Sample size calculation indicated that N
of 20 in each arm would be required to detect a statistically significant difference of this
magnitude with 80% power (β = 0.2). Because SARM1 has been characterized as the final
executioner of axonal degeneration, one could hypothesize that axons lacking SARM1
would have a greater possibility of recovery after injury. However, this also means that
there could potentially be a greater number of axons existing in this state (that are APP+) at
a given time, as Sarm1 deletion has been shown to suppress Wallerian degeneration for
weeks (Henninger et al., 2016). While there is a modest decrease in mean APP area,
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potentially attributed to indirect anti-inflammatory benefits from decreased cellular debris
and microglial activation, it may not be fully representative of the direct neuroprotective
benefits SARM1 loss confers.
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Figure 4. Axonal degeneration and impaired axonal transport in Sarm1-KO and wildtype littermates during chronic EAE as revealed by amyloid precursor protein (APP)
accumulation (42 days post-induction). A) Representative images of Sarm1(-/-) mouse
(lumbar spinocerebellar tract). B) Representative images of wild-type Sarm1(+/+) mouse
(lumbar spinocerebellar tract). C) Mean total area (µm2) of APP by genotype (n=5; 24
images per animal).
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Measuring the difference in percent transected axons between genotypes offers
another measure to analyze the effect SARM1 loss on axonal degeneration. Therefore,
Sarm1-KO and wild-type mice were crossed with Thy1-YFP mice that express yellow
fluorescent protein (YFP) in motor, sensory, and subsets of central neurons. These YFPlabeled axons in the lumbar spinal cords of Sarm1(-/-)/YFP(+) and Sarm1(+/+)/ YFP(+) mice
were analyzed at peak of EAE clinical severity (day 14 post-induction). There was a marked
decrease in percentage of transected axons in Sarm1-KO mice when compared to wild-type
mice (Figure 5). This result suggests that the loss of SARM1 may be particularly protective
against axon degeneration during the early course of EAE, but more samples are needed to
test for statistical significance. It would be of interest to examine axonal degeneration using
the Thy1-YFP mice at later time points in EAE to determine whether such measures of
axonal degeneration correlate with the divergence in clinical score observed in the latter
part of the chronic 42-day EAE time course. In the future, it would be of interest to extend
the chronic EAE time course to see if there are more pronounced, permanent differences in
clinical score between genotypes. This could be facilitated by cognitive behavioral and/or
motor skill tests prior to EAE induction and retesting following EAE resolution. This would
allow for a more translational representation of the therapeutic advantages of SARM1
inactivation in MS and other neuroinflammatory disorders.

30

WT

Sarm1-KO

A

B

YFP

DAPI

% Transected axons

C

YFP

DAPI

0.6
0.5
0.4
0.3
0.2
0.1
0.0
SARM1-KO WT

Figure 5. Axonal degeneration of EAE in Sarm1-KO/YFP+ and Sarm1(+/+)/ YFP+
littermates. Sarm1(-/-)/Thy-1-YFP(+) and Sarm1(+/+)/ Thy-1-YFP (+) mice were actively
induced to undergo EAE. Lumbar cords from the mice were imaged at day 14 post
induction (peak of EAE clinical severity). A) Representative image of Sarm1(-/-)/Thy-1YFP(+) mouse. B) Representative image of Sarm1(+/+)/ Thy-1-YFP (+) mouse. C) Mean percent
of transected axons by genotype (n=2 per genotype; 24 images per animal).
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Sarm1 Bimolecular Fluorescence Complementation
The functional domains of SARM1 (Figure 6B) have been well characterized. The
two tandem sterile alpha motifs (SAM) are responsible for multimerization and the Cterminus Toll/Interleuken-1 receptor (TIR) domain functions to mediate NADase activity
of SARM1 (Gerdts et al., 2013). The N-terminal armadillo/HEAT motif (ARM) domain has
been shown to be autoinhibitory through interaction with the TIR domain (Summers et al.
2016). However, there is still much to be learned regarding the upstream signaling of
SARM1 activation. A molecular tool for in situ detection of SARM1 activation would allow
for a detailed, mechanistic approach to advance our understanding of SARM1 activation.
Figure 6A depicts bimolecular fluorescence complementation (BiFC), a process by
which fluorescence is restored when two non-fluorescent fragments of a fluorescent
protein such as mCitrine are brought into close proximity via fusion to proteins that
undergo protein-protein interaction. This concept was applied to SARM1 as a means of
detecting activation in situ via mCitrine fluorescence. DNA coding for two fragments of
mCitrine (–N172 and –C67) were individually cloned into the pcDNA3.1 vector
downstream of human Sarm1 open reading frame sequence (Figure 6C). This resulted in
SARM1 proteins C-terminally fused to complementary fragments of mCitrine. Figure 6D
illustrates our hypothesis that two SARM1-mCitrine fragment fusion proteins are
conformationally inhibited from BiFC when SARM1 is in its inactive configuration. Relief of
intramolecular ARM inhibition is predicted to allow TIR domain dimerization and mCitrine
complementation and fluorescence.
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Figure 6. SARM1 bimolecular fluorescence complementation (BiFC) A) Cartoon
illustrating bimolecular fluorescence complementation (BiFC). Fluorescence is restored in
non-fluorescent fragments of mCitrine when the fragments are brought together by fusion
of two proteins that undergo protein-protein interaction. B) Schematic diagram of SARM1
functional domains. From left to right: mitochondrial localization signal (MLS), an
autoinhibitory N-terminus region consisting of armadillo/HEAT motifs (ARM), two sterile
alpha motifs (SAM) responsible for multimerization, and a C-terminus Toll/Interleuken-1
receptor (TIR) domain with NADase activity when dimerized. C) Plasmid map illustrating
the DNA sequence for a SARM1-mcitrine fusion protein cloned into the pcDNA3.1
expression vector. D) Cartoon depicting two SARM1 proteins each with different
complementary fragment of mCitrine fused to the TIR domain in an inactive dimer
configuration. E) Cartoon depicting above mentioned SARM1 proteins in active
configuration restoring non-fluorescent fragments of mCitrine with NADase activity.
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The first step in development of a SARM1 BiFC assay was confirming the protein
products of the cloned expression vectors in a eukaryotic system. Several variations of the
two aforementioned SARM1-BiFC constructs were also created as controls using the same
pcDNA3.1 expression vector (Figure 7C). These included plasmids encoding mutant Sarm1
lacking the N-terminal auto-inhibitory domains, theoretically making the corresponding
SARM1 dimer constitutively active and fluorescent; complementary mCitrine fragments
individually cloned without Sarm1; a full-length Sarm1 without mCitrine, but with a FLAGtag (DYKDDDDK epitope); and finally, a full-length mCitrine without Sarm1. HEK293 cells
were transfected with SARM1-mCitrine expression vectors using lipofection, cells were
collected 72 hours later and cell lysates analyzed via western blot. Depending on the BiFC
expression vector, protein products were visualized with anti-GFP (Figure 7A) and/or antiSARM1 (Figure 7B) antibodies. The SARM1-mCitrine BiFC fusion proteins depicted in
Figure 6 were both confirmed using their molecular weight by antibodies directed against
SARM1 and GFP. Additional obstacles regarding effective transfection and expression of
these plasmids in neurons still exist. Experiments to optimize gene dosage to ensure
proper copy number and localization within neurons is still needed as well. Stereological
administration using a viral vector such as a recombinant adeno-associated virus (AAV)
could allow for more precise control over these factors, mitigate damage to transfected
neurons, and allow for broad dissemination within the CNS and to neuronal cultures.
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Figure 7. SARM1-BiFC proteins expressed in HEK293 cells. HEK293 cells were
transfected with SARM1-BiFC expression vectors, cells were collected 72 hours later and
cell lysates analyzed via western blot. Depending on the BiFC expression vector, protein
products were visualized with anti-GFP(A) and/or anti-SARM1(B) antibodies. A) All GFPcontaining SARM1-BiFC protein products and controls were confirmed based on expected
molecular weight (with exception of the C-terminal 67-amino-acid fragment of mCitrine).
B) Each SARM1 protein with different complementary fragment of mCitrine (–N172 and –
C67) was confirmed based on expected molecular weight. C) List of SARM1-BiFC
expression vectors and controls depicted in above western blot with corresponding
molecular weights.
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When assessing the therapeutic potential of SARM1 in MS, the heterogeneous nature
of the various clinical courses in humans and how well the severity and duration of MS
compares in mouse models must be considered. Even though a chronic model of EAE was
used in a majority of analyses, the largely monophasic disease course, and that a majority
of pathology is observed in the spinal cord may have obscured some benefits that SARM1
inactivation may impart during MS. However, the inflammation-induced axonal pathology
observed in the lumbar spinal cord is still relevant to both relapsing-remitting and
progressive courses of MS. The reduction in the severity of EAE in Sarm1-KO compared to
wild-type mice reflected in statistically significant reduction in clinical scores coupled with
reduction in axonal degeneration and transection is a key benchmark for identifying
SARM1 as a rational therapeutic target in the treatment of neuroinflammatory disorders.
Currently there are no pharmacological interventions to inactivate SARM1 in such
disorders, only a theoretical gene therapy using viral vectors to deliver SARM1 dominantnegatives that block axonal degeneration following axotomy (Geisler et al., 2019). However,
the proposed SARM1-BiFC assay has the potential to eventually screen for compounds that
modulate SARM1 activity as well as uncover novel therapeutic targets upstream of SARM1
as our understanding of upstream signaling pathways improves.
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